


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/642,255
	Filing Date	August 15, 2003
	First Named Inventor	Dole et al.
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission <u>4</u> w/refs	Attorney Docket Number	52339AUSM1

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1449 Form with references Return Post Card
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Wendy L. Washtien, Ph.D.
Signature	<i>Wendy L. Washtien</i>
Date	Dec 16, 2003

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Mary Ann Flores
Signature	<i>M. Flores</i>
Date	Dec 16, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



52339AUSM1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Dole *et al.*

:

Serial No. 10/642,255

:

Group Art Unit: Not Yet Known

Filed August 15, 2003

:

Examiner: Not yet known

For: GENE THERAPY FOR CRITICAL LIMB ISCHEMIA WITH WILD-TYPE OR
MUTANT eNOS

Mail Stop Patent Application
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. §1.56 and 1.97 through 1.98, Applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449. As to any reference supplied, applicants do not admit that it is “prior art” under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants’ duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Pursuant to 37 CFR 1.98(d), copies of these documents are not provided herewith, but may be made available to the Examiner if required.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.


Respectfully Submitted,



Wendy L. Washtien, Ph.D. (Reg. No. 36,301)
Patent Agent for Applicants

Date: Dec 16, 2003

Berlex Biosciences
2600 Hilltop Drive
P.O. Box 4099
Richmond, California 94806
Telephone No. 510-262-5411
Facsimile No.: 510-262-7095

FCM PTO-1449 (REV. 1-89)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 52339AUSM1		APPLICATION NO. 10/642,255	
 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Dole et al.			
				FILING DATE August 15, 2003		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	1.	WO 00/28076	18MAY00	PCT			
	2.	WO 00/62605	26OCT00	PCT			
	3.	Fleming, I. et al., "Phosphorylation of Thr ⁴⁹⁵ Regulates Ca ²⁺ /Calmodulin-Dependent Endothelial Nitric Oxide Synthase Activity," <i>Circ Res</i> , 88:e68 -e75; 2001.					
	4.	Govers, R. et al., "Cellular Regulation of Endothelial Nitric Oxide Synthase," <i>Am J Physiol Renal Physiol</i> 280:F193-F206; 2001.					
	5.	Marletta, M. A., "Another Activation Switch for Endothelial Nitric Oxide Synthase: Why does it have to be so complicated," <i>TRENDS in Biochemical Sciences</i> Vol.26:No.9; 2001.					
	6.	Mitchell, B. J. et al., "Coordinated Control of Endothelial Nitric-Oxide Synthase Phosphorylation by Protein Kinase C and the cAMP-dependent Protein Kinase," <i>J. Biol. Chem.</i> , 276: 17625 – 17628; 2001.					
	7.	Smith, R. S. et al., "Human Endothelial Nitric Oxide Synthase Gene Delivery Promotes Angiogenesis in a Rat Model of Hindlimb Ischemia," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22: 1279 – 1285; 2002.					
	8.	Rissanen, T. T. et al., "Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb – on the way to the clinic," <i>Eur J Clin Invest</i> 31(8):651-666; 2001.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							